Trial site
Retina Research Institute of Texas
Abilene, Texas 79606, United StatesNot linked to an institution yet
- 17running trials
- 12closed trials
The trials here
What the 29 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 27 trials
- Phase 1/23 trials
- Phase 12 trials
- Phase 2/31 trial
- Status
- Completed12 trials
- Active, not recruiting11 trials
- Recruiting5 trials
- Not yet recruiting1 trial
- Lead sponsor
- Kodiak Sciences Inc4 trials
- Hoffmann-La Roche3 trials
- Genentech, Inc.2 trials
- Kyowa Kirin Co., Ltd.2 trials
- Regeneron Pharmaceuticals2 trials
- and 16 more
Running trials
Recruiting
A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
NCT07029945· Phase 1/2· Biojiva LLC· Source
Contact: Clinical Study Coordinator
Recruiting
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 in Participants With Diabetic Macular Edema (DME)
NCT07425522· Phase 1· Genentech, Inc.· Source
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
NCT06990399· Phase 3· Kodiak Sciences Inc· Source
Contact: Kodiak Sciences Inc
Recruiting
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PINNACLE
NCT06996080· Phase 3· Kodiak Sciences Inc· Source
Contact: Kodiak Sciences Inc
Not yet recruiting
A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration
NCT06470373· Phase 3· Rophibio, Inc.· Source
Contact: Deisy Villareal
Active, not recruiting
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
NCT06864988· Phase 3· 4D Molecular Therapeutics· Source
Active, not recruiting
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
NCT06779773· Astellas Pharma Global Development, Inc.· Source
Active, not recruiting
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Axitinib Implant) in Subjects With Neovascular Age- Related Macular Degeneration
NCT06495918· Phase 3· Ocular Therapeutix, Inc.· Source
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source
Contact: Clinical Trials Administrator
Active, not recruiting
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer and Tabirafusp Tedromer Compared to Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) - DAYBREAK
NCT06556368· Phase 3· Kodiak Sciences Inc· Source
Active, not recruiting
A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA)
NCT06510816· Phase 3· Annexon, Inc.· Source
Active, not recruiting
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
NCT06491914· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
NCT06373731· Phase 3· Stealth BioTherapeutics Inc.· Source
Active, not recruiting
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916· Phase 2· Kyowa Kirin Co., Ltd.· Source
Active, not recruiting
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153· Phase 1/2· Alcon Research· Source
Active, not recruiting
Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration
NCT05904691· Phase 1· Ocugenix Corporation· Source
Active, not recruiting
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
NCT04108156· Phase 3· Hoffmann-La Roche· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Closed trials
Completed
A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)
NCT06270836· Phase 3· Kodiak Sciences Inc· Source
Completed
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
NCT06116890· Phase 2· Kyowa Kirin Co., Ltd.· Source
Completed
Study to Evaluate Suprachoroidally Administered CLS-AX in the Treatment of Neovascular Age-Related Macular Degeneration
NCT05891548· Phase 2· Clearside Biomedical, Inc.· Source
Completed
Vamikibart in Participants With Uveitic Macular Edema
NCT05642325· Phase 3· Hoffmann-La Roche· Source
Completed
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
NCT05811351· Phase 2· Janssen Research & Development, LLC· Source
Completed
Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study
NCT05797896· Complement Therapeutics· Source
Completed
QA102 Phase II Study in Subjects With Dry AMD
NCT05536752· Phase 2· Smilebiotek Zhuhai Limited· Source
Completed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
NCT06850922· Phase 1/2· Genentech, Inc.· Source
Completed
A Single Ascending Dose Cohort Study of AG-73305 in DME Patients
NCT05301751· Phase 2· Allgenesis Biotherapeutics Inc.· Source
Completed
A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)
NCT05066997· Phase 2/3· Oculis· Source
Completed
A Multicenter, Randomized Study in Participants With Diabetic Retinopathy Without Center-involved Diabetic Macular Edema To Evaluate the Efficacy, Safety, and Pharmacokinetics of Ranibizumab Delivered Via the Port Delivery System Relative to the Comparator Arm
NCT04503551· Phase 3· Hoffmann-La Roche· Source
Completed
A Study to Evaluate THR-149 Treatment for Diabetic Macular Oedema
NCT04527107· Phase 2· Oxurion· Source
Report an error